Author:
Chottanapund Suthat,Van Duursen Majorie B.M.,Navasumrit Panida,Hunsonti Potchanee,Timtavorn Supatchaya,Ruchirawat Mathuros,Van den Berg Martin
Funder
Chulabhorn Graduate Institute
Chulabhorn Research Institute (Thailand)
The Institute for Risk Assessment Sciences at the Utrecht University (The Netherlands)
Subject
Cell Biology,Clinical Biochemistry,Endocrinology,Molecular Biology,Molecular Medicine,Biochemistry,Endocrinology, Diabetes and Metabolism
Reference60 articles.
1. GLOBOCAN, S.o.C.I., Breast Cancer Incidence and Mortality Worldwide in 2008, International Agency for Research on Cancer, 2008.
2. Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer;Guth;British Journal of Cancer,2008
3. Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer;Miles;Breast Cancer Research,2009
4. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities;Conlin;Clinical Breast Cancer,2008
5. Estrogen induced breast cancer is the result in the disruption of the asymmetric cell division of the stem cell;Russo;Hormone Molecular Biology and Clinical Investigation,2011
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献